Author of the publication

Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials.

, and . Progress in cardiovascular diseases, 49 (4): 284-99 (2007)5396<m:linebreak></m:linebreak>LR: 20071115; JID: 0376442; 0 (Anticoagulants); 0 (Platelet Aggregation Inhibitors); RF: 39; ppublish;<m:linebreak></m:linebreak>Tests d&#039;equivalència.
DOI: 10.1016/j.pcad.2006.10.001

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Trials and tribulations of non-inferiority: the ximelagatran experience., , and . Journal of the American College of Cardiology, 46 (11): 1986-95 (December 2005)4428<m:linebreak></m:linebreak>LR: 20071115; PUBM: Print-Electronic; DEP: 20051109; JID: 8301365; 0 (Anticoagulants); 0 (Azetidines); 0 (Benzylamines); 0 (ximelagatran); 81-81-2 (Warfarin); CIN: J Am Coll Cardiol. 2006 Sep 5;48(5):1058; author reply 1059. PMID: 16949503; 2005/05/21 received; 2005/07/06 revised; 2005/07/11 accepted; 2005/11/09 aheadofprint; ppublish;<m:linebreak></m:linebreak>Tests d&#039;equivalència.Relationship of aspirin use with age-related macular degeneration: association or causation?: comment on "The association of aspirin use with age-related macular degeneration"., and . JAMA internal medicine, 173 (4): 264-6 (February 2013)JID: 101589534; ppublish; Exemple de l&#039;aplicació dels criteris de Bradford Hill a l&#039;estudi d&#039;AAS i DME;<m:linebreak></m:linebreak> <m:linebreak></m:linebreak>Causalitat; Exemple.Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials., and . Progress in cardiovascular diseases, 49 (4): 284-99 (2007)5396<m:linebreak></m:linebreak>LR: 20071115; JID: 0376442; 0 (Anticoagulants); 0 (Platelet Aggregation Inhibitors); RF: 39; ppublish;<m:linebreak></m:linebreak>Tests d&#039;equivalència.